Zobrazeno 1 - 10
of 35
pro vyhledávání: '"S. Peter Wu"'
Autor:
Leah M. Katz, Victor Ng, S. Peter Wu, Sherry Yan, David Grew, Samuel Shin, Nicholas W. Colangelo, Allison McCarthy, Harvey I. Pass, Abraham Chachoua, Peter B. Schiff
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectivesTo investigate the efficacy and safety of lung stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) including oligorecurrent and oligoprogressive disease.MethodsSingle-institution retrospective analysis of 60 NS
Externí odkaz:
https://doaj.org/article/5e041cac3eff420f931de82b88a4f085
Autor:
Ola Landgren, Gareth Morgan, Brian A. Walker, Nikhil C. Munshi, Mark van Duin, Pieter Sonneveld, Sham Mailankody, Inhye E. Ahn, Ruth M. Pfeiffer, S. Peter Wu
Purpose: The poor prognosis of multiple myeloma with t(4;14) is driven by the fusion of genes encoding multiple myeloma SET domain (MMSET) and immunoglobulin heavy chain. Specific genes affected by MMSET and their clinical implications in non-MMSET m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d8ddb7038d8f42774bd0d86b8b4e8f2
https://doi.org/10.1158/1078-0432.c.6522947.v1
https://doi.org/10.1158/1078-0432.c.6522947.v1
Autor:
Ola Landgren, Gareth Morgan, Brian A. Walker, Nikhil C. Munshi, Mark van Duin, Pieter Sonneveld, Sham Mailankody, Inhye E. Ahn, Ruth M. Pfeiffer, S. Peter Wu
Supplemental Table 1 contains a comparison of hazard ratios of Non-MMSET patients at the highest quartile (Q4 Risk) and MMSET patients. Supplemental Table 2 contains a list of gene signatures from sensitivity analyses. Supplemental Table 3 contains a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b97850291f02895ad157beeb9f30da6
https://doi.org/10.1158/1078-0432.22455155.v1
https://doi.org/10.1158/1078-0432.22455155.v1
Publikováno v:
Breast Cancer Research and Treatment. 187:815-830
Anti-HER2 therapy delivered in the adjuvant setting for breast cancer is given in conjunction with cytotoxic chemotherapy. For HER2-positive (HER2+) patients who cannot tolerate chemotherapy, there is no randomized data regarding the role of anti-HER
Publikováno v:
Cancer Research. 80:P1-18
Purpose: The development of trastuzumab has significantly improved prognosis and treatment of Her2 positive breast cancer. The efficacy of trastuzumab monotherapy is limited and thus standard of care is to combine trastuzumab with chemotherapy. Yet f
Autor:
David Schreiber, Clifford M. Chang, Zujun Li, Babak Givi, S. Peter Wu, Jamie R Oliver, Kenneth S. Hu
Publikováno v:
Otolaryngology–Head and Neck Surgery. 162:881-887
To analyze the patterns of care and survival of cutaneous angiosarcomas of the head and neck.Retrospective cohort study.National Cancer Database.The National Cancer Database was queried to select patients with cutaneous angiosarcoma of the head and n
Autor:
S. Peter Wu, Juhi M. Purswani, C.A. Perez, F. Shaikh, Freya Schnabel, Naamit K. Gerber, Nelly Huppert, Jennifer Chun Kim
Publikováno v:
World Journal of Clinical Oncology
BACKGROUND Patients with an in-breast tumor recurrence (IBTR) after breast-conserving therapy have a high risk of distant metastasis and disease-related mortality. Classifying clinical parameters that increase risk for recurrence after IBTR remains a
Publikováno v:
Breast cancer research and treatment. 187(3)
Anti-HER2 therapy delivered in the adjuvant setting for breast cancer is given in conjunction with cytotoxic chemotherapy. For HER2-positive (HER2+) patients who cannot tolerate chemotherapy, there is no randomized data regarding the role of anti-HER
Publikováno v:
Annals of surgical oncology. 28(11)
Young women with ductal carcinoma in situ (DCIS) represent a unique cohort given considerations for future risk reduction and treatment effects on fertility and quality of life. We evaluated national patterns of care in the treatment of young women a
Autor:
Jerome M. Karp, S. Peter Wu, Naamit K. Gerber, Bhartesh A. Shah, Michael L. Grossbard, Cheongeun Oh
Publikováno v:
Clinical lymphoma, myelomaleukemia. 20(12)
Treatment for early-stage Hodgkin lymphoma (HL) involves radiotherapy (RT), chemotherapy, or combined modality therapy (CMT). We analyzed reduction of RT dose in CMT, particularly in the context of German Hodgkin Study Group (GHSG) HD10 randomized tr